US OptionsDetailed Quotes
VSTM241220P2000
- 0.05
- 0.000.00%
15min DelayTrading Nov 19 09:31 ET
0.00High0.00Low
0.00Open0.05Pre Close0 Volume182 Open Interest2.00Strike Price0.00Turnover191.13%IV51.79%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0486Delta0.0499Gamma80.90Leverage Ratio-0.0040Theta-0.0002Rho-3.93Eff Leverage0.0011Vega
Verastem Stock Discussion
Pretty damn good run so far. I only managed to hop on in Sept.
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
Verastem Oncology (VSTM) has completed its rolling New Drug Application (NDA) to the FDA for avutometinib plus defactinibcombination therapy for adults with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC). The company is seeking accelerated approval and priority review, with a potential FDA ap...
Robust overall response rates observed (31% overall, 44% in KRAS mutant, 17% in KRAS wild-type) in patients whose cancer had progressed despite prior treatment with chemotherapy and/or MEK inhibitors and/or bevacizumabPatients on avutometinib and defactinib achieved a median progression free survival of more than one year (12.9 months)...
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting
Verastem Oncology presented updated data from the Phase 2 RAMP 201 trial evaluating avutometinib and defactinibcombination in recurrent low-grade serous ovarian cancer (LGSOC) at the IGCS 2024 Annual Meeting. Key findings include:
- 31% overall response ...
BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced further details for its late-breaking presentation of mature data from the ongoing Phase 2 RAMP 201 (ENGOT-ov60/G...
No comment yet